See more : Capital One Financial Corporation (COF-PK) Income Statement Analysis – Financial Results
Complete financial analysis of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biohaven Pharmaceutical Holding Company Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- BIGG Digital Assets Inc. (BBKCF) Income Statement Analysis – Financial Results
- FutureChem Co.,Ltd (220100.KQ) Income Statement Analysis – Financial Results
- Fuan Pharmaceutical (Group) Co., Ltd. (300194.SZ) Income Statement Analysis – Financial Results
- Electricity Generating Authority Of Thailand- North Bangkok Power Plant Block 1 Infrastructure Fund (EGATIF.BK) Income Statement Analysis – Financial Results
- The Goldman Sachs Group, Inc. (GS-PA) Income Statement Analysis – Financial Results
Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
About Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 462.51M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.37M | 1.39M | 91.66M | 72.00K | 0.00 | 0.00 |
| Gross Profit | -3.37M | -1.39M | 370.85M | -72.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 80.18% | 0.00% | 0.00% | 0.00% |
| Research & Development | 373.28M | 437.07M | 181.49M | 98.46M | 344.67M | 0.00 |
| General & Administrative | 56.90M | 130.86M | 37.41M | 16.05M | 134.45M | 0.00 |
| Selling & Marketing | 5.87M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 62.77M | 130.86M | 37.41M | 16.05M | 134.45M | 0.00 |
| Other Expenses | 0.00 | -1.91M | 1.21M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 436.05M | 567.93M | 218.90M | 114.51M | 479.12M | 0.00 |
| Cost & Expenses | 436.05M | 567.93M | 218.90M | 114.51M | 479.12M | 0.00 |
| Interest Income | 17.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | -12.71M | 0.00 |
| Depreciation & Amortization | 6.91M | 1.39M | 1.39M | 72.00K | 171.86K | 52.52K |
| EBITDA | -429.14M | -462.80M | -217.51M | -114.43M | -479.12M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | -47.03% | 0.00% | 0.00% | 0.00% |
| Operating Income | -436.05M | -567.93M | -218.90M | -114.51M | -479.12M | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% | -47.33% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 26.50M | -1.91M | 6.47M | -4.16M | -49.26M | 0.00 |
| Income Before Tax | -409.55M | -569.84M | -212.43M | -118.67M | -528.39M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | -45.93% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.38M | 438.00K | 1.37M | -134.30K | 419.00K | 0.00 |
| Net Income | -408.17M | -570.28M | -213.80M | -118.67M | -528.81M | 0.00 |
| Net Income Ratio | 0.00% | 0.00% | -46.23% | 0.00% | 0.00% | 0.00% |
| EPS | -5.73 | -12.75 | -5.97 | -3.31 | -10.91 | 0.00 |
| EPS Diluted | -5.73 | -12.75 | -5.97 | -3.31 | -10.91 | 0.00 |
| Weighted Avg Shares Out | 71.20M | 44.74M | 35.82M | 35.82M | 48.49M | 0.00 |
| Weighted Avg Shares Out (Dil) | 71.20M | 44.74M | 35.82M | 35.82M | 48.49M | 0.00 |
Pfizer to Acquire Biohaven Pharmaceuticals
Pfizer to Acquire Biohaven Pharmaceuticals
Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
Pfizer and Biohaven's VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment
Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States
Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States
Photo of Biohaven Pharmaceuticals Ringing the Opening Bell Available on Business Wire's Website and the Associated Press Photo Network
Source: https://incomestatements.info
Category: Stock Reports